Piramal Enterprises Ltd. said its pain relief tablet brand Saridon has been exempted from the list of banned fixed dose combinations by the Supreme Court.
In a regulatory filing, the company said the apex court has ruled in favour of Saridon, which is a heritage brand from its healthcare product portfolio.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
"In September 2018, PEL had been awarded a stay order from the Supreme Court on the ban, which allowed it to continue manufacturing, distribution and sale of the FDC," it said.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Commenting on the court order, PEL Executive Director Nandini Piramal said, "We are pleased with the Supreme Court ruling, as it is an affirmation to our commitment to provide effective and safe healthcare solutions that address unique needs of Indian consumers. We were confident that the law would prevail in our favour."
Last year in September, the government had banned 328 FDCs, which were termed “irrational” on the basis of safety issues and lack of therapeutic justification.
Stating that Saridon is a "heritage brand trusted by customers for the last 50 years in India", Piramal said: "This exemption from the banned list of FDCs validates our intent to serve our customers with the highest levels of integrity."
"We continue to expand our healthcare product portfolio with an aim to be amongst the top three over-the-counter product companies in India by 2020," Piramal further said,
Piramal Enterprises said the addressable analgesic market is Rs 6,450 crore, of which analgesic tablet market is Rs 2,050 crore as of December 2018, citing an AC Nielsen report. The popularity of the brand is widespread with 31 tablets being sold every second.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
